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In advanced pancreatic cancer, level one evidence has established a significant survival advantage with chemotherapy, compared to
best supportive care. The treatment-associated toxicity needs to be evaluated. This study examines the secondary outcome
measures for chemotherapy in advanced pancreatic cancer using meta-analyses. A systematic review was undertaken employing
Cochrane methodology, with search of databases, conference proceedings and trial registers. The secondary end points were
progression-free survival (PFS)/time to progression (TTP) (summarised using the hazard ratio (HR)), response rate and toxicity
(summarised using relative risk). There was no significant advantage of 5FU combinations vs 5FU alone for TTP (HR¼1.02; 95%
CI¼0.85–1.23) and toxicity. Progression-free survival (HR 0.78; CI 0.70–0.88), TTP (HR¼0.85; 95% CI¼0.72–0.99) and overall
response rate (RR¼0.56; 95% CI¼0.46–0.68) were significantly better for gemcitabine combination chemotherapy, but offset by
the greater grade 3/4 toxicity thrombocytopenia (RR¼1.94; 95% CI¼1.32–2.84), leucopenia (RR¼1.46; 95% CI¼1.15–1.86),
neutropenia (RR¼1.48; 95% CI¼1.07–2.05), nausea (RR¼1.77; 95% CI¼1.37–2.29), vomiting (RR¼1.64; 95% CI¼1.24–2.16)
and diarrhoea (RR¼2.73; 95% CI¼1.87–3.98). There is no significant advantage on secondary end point analyses for administering
5FU in combination over 5FU alone. There is improved PFS/TTP and response rate, with gemcitabine-based combinations, although
this comes with greater toxicity.
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Advanced pancreatic cancer has a poor prognosis, with a median
survival of 2–6 months for metastatic disease and 6–11 months
for locally advanced disease (Cancer Research, 2006). Chemother-
apy with fluoropyrimidines, gemcitabine, either alone or in
combination with other agents (Rocha Lima and Flores, 2006),
and chemoradiation are all used in the palliative setting (Mancuso
et al, 2006). Overall survival meta-analyses, using relative risk (Yip
et al, 2006) or the hazard ratio (HR) (Fung et al, 2003; Sultana et al,
2007), have established a role for chemotherapy over best
supportive care. Questions have arisen as to the cost at which
this survival advantage is gained, in particular, the toxicity profile.
Following from our previous survival meta-analysis (Sultana et al,
2007), we present the results of the secondary outcome measures
meta-analysis.
There has only been one fully published meta-analysis evaluat-
ing secondary outcome measures, with no pooling of the results of
these end points (Yip et al, 2006). Other published reports have
assessed this only for the comparison of gemcitabine combinations
vs gemcitabine. (Liang, 2005; Milella et al, 2006; Heinemann et al,
2006a; Xie et al, 2006a,b; Bria et al, 2007; Heinemann et al, 2007).
To fully evaluate the risks vs the benefits of treatment, a
comprehensive evaluation including assessment of several com-
posite end points is required.
METHODS
Detailed description of the methodology of the systematic review
has already been described (Sultana et al, 2007).
The secondary outcome measures evaluated were progression-
free survival (PFS – time from randomisation to progression or
death) or time to progression (TTP – time from randomisation to
disease progression), overall response rate (ORR – number of
partial and complete responses) and toxicity (as published by the
trialists, was recorded, with the most frequently reported events
analysed).
Individual trial level time to event data (PFS/TTP) were
summarised by the log HR and its variance was approximated
using previously reported methods (Parmar et al, 1998;
Williamson et al, 2002). Trial level log HRs and their variances
were pooled using an inverse variance, weighted average and
results presented as a HR and 95% confidence interval.
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relative risks and 95% confidence intervals and pooled using the
Mantel–Haenszel method for combining trials (Deeks et al, 2001).
Heterogeneity was assessed by visual inspection of the Forrest plot,
the Cochran’s w
2 test (using a 10% significance level, in view of the
low power of tests for heterogeneity (Paul and Donner, 1992)) and
interpretation of the I
2 statistic (percentage of variation due to
heterogeneity with higher values indicating a greater degree of
heterogeneity) (Deeks et al, 2004). A fixed effect approach was
adopted unless there was evidence of significant unexplained
heterogeneity in which case a random effects approach was used.
RESULTS
Results are presented for the comparisons with adequate data to
assess the secondary outcome measures.
5FU vs 5FU combination chemotherapy
There were five studies (Supplementary Table 1) (Kovach et al,
1974; Cullinan et al, 1985, 1990; Ducreux et al, 2002; Maisey et al,
2002) (n¼700) included in this comparison. A HR of o1 indicates
a survival advantage for 5FU combination chemotherapy.
Two trials assessed TTP (Figure 1) and found no significant
advantage for 5FU combinations over 5FU alone (HR¼1.02; 95%
CI¼0.85–1.23). For PFS, 5FU combination appeared better than
5FU alone (two trials; 416 patients; HR¼0.67; 95% CI¼0.46–
0.98). The ORR (Figure 2) was superior (five trials; 700 patients;
RR¼0.43; 95% CI¼0.25–0.74) in the 5FU combination arm.
Grade 3 or 4 vomiting was significantly greater in the 5FU
combination chemotherapy arm (two trials; 320 patients;
RR¼3.76; 95% CI¼1.67–8.44). There was a higher occurrence
of diarrhoea (two trials 406 patients; RR¼1.49; 95% CI¼0.58–
3.84), stomatitis (three trials; 529 patients; RR¼1.29; 95%
CI¼0.75–2.22) and thrombocytopenia (two trials; 332 patients;
RR¼2.15; 95% CI¼0.83–5.53) in the combination chemotherapy
arm (Figure 3). Data for leucopenia, neutropenia, anaemia and
nausea are displayed in Figure 3. There was significant between
trial heterogeneity in the PFS analysis, unlike for the TTP and
response rate analyses.
Gemcitabine vs 5FU
Two randomised controlled trials involving 197 patients were
assessed (Burris et al, 1997; Cantore et al, 2004), including
unpublished individual patient data (Cantore et al, 2004). A HR of
o1 indicates a survival advantage for gemcitabine. Gemcitabine
resulted in survival advantage on TTP analysis, (HR¼0.46; 95%
CI¼0.31–0.70), but not for PFS analysis (HR¼0.94; 95%
CI¼0.58–1.53).
Overall response rate appeared better in the gemcitabine arm;
however, the wide confidence interval suggests a benefit for either
gemcitabine or 5FU (one trial; 126 patients; RR¼0.14; 95%
CI¼0.01–2.66). In the Burris trial (Burris et al, 1997), haemato-
logical toxicity was seen more frequently following gemcitabine
therapy (grades 3 and 4 neutropenia in 25% of gemcitabine and
4.9% of 5FU patients; Po0.001).
Gemcitabine vs gemcitabine-based combination
chemotherapy
Nineteen studies involving 4697 patients were included (Supple-
mentary Table 2) (Berlin et al, 2002; Colucci et al, 2002; Wang et al,
2002; Heinemann et al, 2003; Scheithauer et al, 2003; Li and Chao,
2004; Ohkawa, 2004; Rocha Lima et al, 2004; Viret et al, 2004;
Cunningham et al, 2005; Di Costanzo et al, 2005; Hermann et al,
2005; Louvet et al, 2005; Oettle et al, 2005; Reiss et al, 2005; Reni
et al, 2005; Stathopoulos et al, 2005; Abou-Alfa et al, 2006; Poplin
et al, 2006). Data from four of the included studies (Abou-Alfa
et al, 2006; Heinemann et al, 2006b; Stathopoulos et al, 2006;
Herrmann et al, 2007) were based on abstracts and extra data
provided by the authors (Hermann et al, 2005; Stathopoulos et al,
2005). A HR of o1 indicates a survival advantage for gemcitabine-
based combination chemotherapy.
Progression-free survival (four trials; 864 patients; HR¼0.78;
95% CI¼0.70–0.88), TTP (3 trials; 559 patients; HR¼0.85; 95%
CI¼0.72–0.99) (Figure 4) and ORR (Figure 5) (17 trials; 3577
patients; RR¼0.56; 95% CI¼0.46–0.68) were significantly better
in the gemcitabine combination chemotherapy arm. Haematolo-
gical toxicity was greater in the gemcitabine combination
chemotherapy arm (Figure 6), including thrombocytopenia (18
trials; 4564 patients; RR¼1.94; 95% CI¼1.32–2.84), leucopenia
(eight trials; 1606 patients; RR¼1.46; 95% CI¼1.15–1.86),
neutropenia (15 trials; 3818 patients; RR¼1.48; 95% CI¼1.07–
2.05) and anaemia (15 trials; 3745 patients; RR¼1.14; 95%
CI¼0.82–1.59). Gastrointestinal side effects (Figure 7) of nausea
(nine trials; 3055 patients; RR¼1.77; 95% CI¼1.37–2.29),
vomiting (10 trials; 3471 patients; RR¼1.64; 95% CI¼1.24–
2.16) and diarrhoea (14 trials; 3531 patients; RR¼2.73; 95%
CI¼1.87–3.98) were significantly increased, with a trend towards
increased stomatitis (7 trials; 2007 patients; RR¼1.84; 95%
CI¼0.86–3.92) in the gemcitabine combination chemotherapy
arm. There was no significant inter-trial heterogeneity for the end
points of PFS, TTP and ORR.
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Figure 1 5FU single agent vs 5FU-based combination chemotherapy – PFS/TTP analyses.
Chemotherapy in advanced pancreatic cancer
A Sultana et al
7
British Journal of Cancer (2008) 99(1), 6–13 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sStudy
or subcategory
Test for overall effect: Z=3.09 (P=0.002)
Test for heterogeneity: χ2=6.74, d.f.=4 (P=0.15), I2=40.7%
Total events: 16 (5FU), 39 (5FU combination)
Total (95% CI) 291 283 100.00 0.43 (0.25, 0.74)
Kovach 1974
Cullinan 1985
Cullinan 1990
Ducreux 2002
Maisey N 2002
0.001 0.01 0.1 1 10 100 1000
Favours 5FU combin Favours 5FU
5FU 5FU combination
n/N n/N
3/14
3/10
1/64
0/98
9/105
8/21
1/13
2/59
10/98
18/92
RR (fixed)
95% CI
RR (fixed)
95% CI
Weight
%
16.39
2.23
5.33
26.90
49.15
0.56
3.90
0.46
0.05
0.44
(0.18, 1.76)
(0.04, 4.95)
(0.00, 0.80)
(0.21, 0.93)
(0.47, 32.09)
Legend: n=number of responses
N=total number of patients
Figure 2 5FU single agent vs 5FU-based combination chemotherapy – response rate analyses.
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Figure 3 5FU single agent vs 5FU-based combination chemotherapy – toxicity analyses.
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possibly publication bias, but this is difficult to interpret in view of
the small number of studies within each comparison.
DISCUSSION
5FU combinations did not prolong TTP over 5FU alone, despite
significantly better response rate with the former. The study of Yip
et al (2006) assessed the parameters described in our analyses, but
did not pool the results unlike our approach. In the two trials that
had assessed PFS, the overall summary estimate favoured 5FU
combination chemotherapy, but there was significant inter-trial
heterogeneity. This may be due to the differences in dosing. The
dose of 5FU administered was lower in the Maisey et al (2002)
study (300mgm
 2day
 1 in both arms) compared to the Ducreux
et al (2002) study (500mgm
 2day
 1 used in the single-agent arm
and 1000mgm
 2 used in the combination arm).
As overall survival is a better indicator of efficacy than response
rate (Maisey et al, 2002), the evidence from these end points,
interpreted alongside the overall survival result (Sultana et al,
2007), do not support the use of 5FU combinations over 5FU single
agent.
Meta-analyses of the secondary end points were not possible in
the gemcitabine vs 5FU comparison, as these results were only
available for one randomised trial.
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Figure 4 Results for gemcitabine vs gemcitabine-based combination chemotherapy – TTP/PFS.
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Figure 5 Results for gemcitabine vs gemcitabine-based combination chemotherapy – response rate.
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gemcitabine-based combinations vs gemcitabine employed differ-
ing survival analyses methodology (Liang, 2005; Heinemann et al,
2006a; Milella et al, 2006; Xie et al, 2006a). In contrast to these
reports, our survival analyses were conducted using the HR, which
is the ideal measure for time-to-event analyses, as it accounts for
both censoring of data and the time it takes for the event (such as
death or progression) to occur (Parmar et al, 1998).
For gemcitabine-based chemotherapy vs gemcitabine alone, our
findings of improved PFS/TTP are in agreement with the meta-
analyses of Xie et al (2006b). Better ORR with the combination
regimens was in keeping with the studies of Xie et al and Milella
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Legend: n=number of toxicity events
N=total number of patients
Figure 6 Results for gemcitabine vs gemcitabine-based combination chemotherapy – haematological toxicity.
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set al (Xie et al, 2006b), while increased toxicity profile was noted
by Xie et al (2006b). The meta-analyses that examined gemcitabine
plus a platinum agent vs gemcitabine alone found better PFS/TTP
in the combination arm (Xie et al, 2006a; Heinemann et al, 2007),
significant improvement in ORR (Heinemann et al, 2007) and
greater toxicity (Xie et al, 2006a).
We have done our utmost to cover most reported end points in
the randomised controlled trials. We could not address quality of
life due to the different methods used for reporting quality of life.
Although we have pooled the response rate and adverse events
data across studies to permit a clinically relevant analysis,
reporting of these parameters varied. Response rates were reported
using clinical parameters, the WHO and RECIST criteria, whereas
the CTC, WHO and ECOG scales were used for toxicity data.
To conclude, there is insufficient evidence to suggest a
TTP, response rate and toxicity advantage in administering
5FU in combination with other chemotherapy agents over
5FU alone. There is a small but significant TTP/PFS advantage,
as well as improved response rate, with gemcitabine-based
combinations, and this provides a justification for the use of these
agents, despite their greater toxicity. An area for further
randomised controlled trials to assess is which gemcitabine-based
combination chemotherapy regimens are least toxic, while
retaining all the other advantages of the combination approach.
Study
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1.93 (1.10, 3.38)
0.61 (0.06, 6.51)
2.12 (1.28, 3.52)
2.93 (0.63, 13.68)
16.76 2.76 (1.07, 6.64)
2.63 (0.71, 9.74)
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4.00 (0.86, 18.67)
1.03 (0.41, 2.54)
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0.75 (0.17, 3.26)
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1.41
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2.67 (0.72, 9.95)
3.16 (0.69, 14.48)
Legend: n=number of toxicity events
N=total number of patients
Figure 7 Results for gemcitabine vs gemcitabine-based combination chemotherapy – gastrointestinal toxicity.
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